A Shimadzu micro-scale HPLC system for analysis of nanobody repertoires

用于分析纳米抗体库的岛津微型 HPLC 系统

• 批准号: 10794691
• 负责人: Yi Shi
• 金额: $ 8.68万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-10 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10794691
• 关键词: Affinity; Antibodies; Binding; Biomedical Engineering; Biophysics; Development; Devices; Funding; High Pressure Liquid Chromatography; Hybrids; Methods; Microbe; Proteins; Proteomics; Science; Systems Analysis; Technology; Therapeutic; antigen binding; cost; disease diagnosis; monomer; nanobodies; tool

PROJECT SUMMARY/ABSTRACT Camelid VHH antibodies or Nanobodies are a compelling new class of antibodies for biomedical applications. Nanobodies are characterized by small size, robust fold, and high stability. Despite their small size and monomeric binding, they retain high affinity and selectivity for antigen binding. In addition, nanobodies can be readily produced with low cost from microbes. They are ideal modular proteins for bioengineering and have shown promising potential in facilitating disease diagnosis and therapy. Here we propose to develop integrative technologies to facilitate nanobody discovery and characterization. In parallel, we will apply our methods and tool nanobodies to enable biomedical discoveries and therapeutics. In this supplement application, we request funds to obtain a sensitive HPLC device (Shimazu HPLC Nexera 40) to support our proposed science related to nanobody identification and biophysical, structural and functional characterizations.

项目总结/摘要 骆驼VHH抗体或纳米抗体是用于生物医学应用的引人注目的新型抗体。 纳米抗体的特征在于小尺寸、稳健折叠和高稳定性。尽管它们的体积很小， 在单体结合中，它们保留了对抗原结合的高亲和力和选择性。此外，纳米抗体可以是 易于从微生物中以低成本生产。它们是生物工程的理想模块蛋白， 显示出在促进疾病诊断和治疗方面的有希望的潜力。 在这里，我们建议开发综合技术，以促进纳米抗体的发现和表征。在 与此同时，我们将应用我们的方法和工具纳米抗体，使生物医学发现和治疗。在 在此补充申请中，我们申请资金以获得灵敏的HPLC装置（Shimazu HPLC Nexera 40） 支持我们提出的与纳米抗体鉴定和生物物理，结构和功能相关的科学 特征化。

项目成果

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.

• DOI: 10.1126/sciadv.abh0319
• 发表时间: 2021-05
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Nambulli S;Xiang Y;Tilston-Lunel NL;Rennick LJ;Sang Z;Klimstra WB;Reed DS;Crossland NA;Shi Y;Duprex WP
• 通讯作者: Duprex WP